References
- 1
Argo T R, Carnahan R M, Perry P J.
Aripiprazole, a novel atypical antipsychotic drug.
Pharmacotherapy.
2004;
24
212-228
- 2
Casey D E, Carson W H, Saha A R, Liebeskind A, Ali M W, Jody D. et al .
Switching patients to aripiprazole from other antipsychotic agents: a multicenter
randomized study.
Psychopharmacology.
2004;
166
391-399
- 3
McQuade R D, Stock E, Marcus R, Jody D, Gharbia N A, Vanveggel S. et al .
A Comparison of Weight Change During Treatment With Olanzapine or Aripiprazole: Results
From a Randomized, Double-Blind Study.
J Clin Psychiatry.
2004;
65 (Suppl. 18)
47-56
- 4
Sacks F M.
Metabolic Syndrome: epidemiology and consequences.
J Clin Psychiatry.
2004;
65 (Suppl. 18)
3-12
- 5
Semba J, Watanabe A, Kito S, Toru M.
Behavioural and neurochemical effects of OPC-14 597, a novel antipsychotic drug, on
dopaminergic mechanisms in rat brain.
Neuropharmacology.
1995;
34
785-791
- 6
Wirshing D A.
Schizophrenia and obesity: impact of antipsychotic medications.
J Clin Psychiatry.
2004;
65 (Suppl. 18)
13-26
Gudrun Luebbe
Social Psychiatry and Psychotherapy
Medical School Hannover
30163 Hannover
Germany
eMail: Luebbe.Gudrun@mh-hannover.de
